Prostate cancer screening reduces mortality risk by almost half, according to a Swedish study.
Researchers studied 10,000 men, aged 50 to 65 years, to assess the merits of prostate-specific antigen screening.
Prostate cancer was diagnosed in 1,138 men in a group who underwent PSA screening and 718 in a control group. During 14 years of follow-up, prostate cancer mortality in the screening group was almost half that of the control group. The findings were published online in the The Lancet Oncology.
Introducing Nursing Times Learning
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Click on the topics below to get started: